Anastrozole is a widely prescribed aromatase inhibitor used to treat hormone receptor-positive breast cancer in postmenopausal women across the UK. Whilst this medication is generally well-tolerated during long-term therapy, patients and healthcare professionals occasionally raise questions about its potential impact on liver health, particularly in relation to fatty liver disease. Understanding the relationship between anastrozole and hepatic function is important for safe, effective cancer management. This article examines current evidence on anastrozole's effects on the liver, explores fatty liver disease risk factors, and provides practical guidance on monitoring and maintaining liver health during treatment, in line with NICE, MHRA, and NHS recommendations.

What Is Anastrozole and How Does It Work?

Anastrozole is an aromatase inhibitor licensed in the UK for the treatment of hormone receptor-positive breast cancer in postmenopausal women. It is commonly prescribed both as adjuvant therapy following surgery and for advanced breast cancer. The medication works by blocking the enzyme aromatase, which is responsible for converting androgens into oestrogen in peripheral tissues.

By significantly reducing circulating oestrogen levels—by approximately 80% in postmenopausal women—anastrozole deprives oestrogen-dependent breast cancer cells of the hormonal signals they need to grow and multiply. This mechanism makes it effective in reducing the risk of cancer recurrence and slowing disease progression in appropriate patients, as outlined in NICE guidance (NG101) and the MHRA Summary of Product Characteristics (SmPC).

Anastrozole is typically administered as a 1 mg oral tablet taken once daily, and treatment duration often extends for five years or longer, depending on individual risk factors and clinical response. The medication is generally well-tolerated, though like all systemic therapies, it carries a profile of potential adverse effects.

Common side effects include:

• Hot flushes and night sweats

• Joint pain and stiffness (arthralgia)

• Bone thinning (osteoporosis)

• Fatigue and weakness

• Nausea and headache

Hepatic adverse reactions are uncommon but can occur. The SmPC notes that increases in liver enzymes (ALT, AST, alkaline phosphatase) have been reported, and rare cases of hepatitis and jaundice have been documented. Patients should seek medical review if they develop symptoms suggestive of liver dysfunction.

Important interaction: Anastrozole should not be taken with tamoxifen or oestrogen-containing therapies, as these can reduce its effectiveness.

Whilst anastrozole may affect lipid profiles and metabolic parameters, patients and healthcare professionals occasionally raise concerns about potential impacts on liver function. Understanding how anastrozole interacts with hepatic health, particularly in relation to fatty liver disease, is important for safe and effective long-term management.

Reporting side effects: If you experience any side effects, talk to your doctor or pharmacist. You can also report suspected side effects via the Yellow Card Scheme at yellowcard.mhra.gov.uk or through the Yellow Card app.

Understanding Fatty Liver Disease: Causes and Symptoms

Fatty liver disease, medically termed hepatic steatosis, occurs when excess fat accumulates in liver cells. In the UK, this condition has become increasingly prevalent, affecting an estimated 20–30% of the general adult population. There are two main categories: alcohol-related liver disease (ARLD), caused by excessive alcohol consumption, and non-alcoholic fatty liver disease (NAFLD), which develops in people who drink little or no alcohol.

NAFLD is strongly associated with metabolic risk factors, including:

• Obesity and increased waist circumference

• Type 2 diabetes and insulin resistance

• Dyslipidaemia (elevated cholesterol and triglycerides)

• Hypertension

• Metabolic syndrome

In most cases, fatty liver disease causes no symptoms in its early stages, which is why it is often discovered incidentally during imaging studies or routine blood tests. When symptoms do occur, they may include persistent fatigue, discomfort in the upper right abdomen, or a general sense of malaise. More advanced disease can progress to non-alcoholic steatohepatitis (NASH), characterised by inflammation and liver cell damage, and eventually to cirrhosis or liver failure if left unmanaged.

Diagnosis typically involves blood tests to check liver enzymes (ALT, AST, GGT), though it is important to note that normal liver enzymes do not exclude the presence of steatosis or fibrosis. Ultrasound imaging may reveal increased liver echogenicity suggestive of fat accumulation.

NICE guidance (NG49) recommends risk stratification using non-invasive scoring systems:

• FIB-4 score (age-adjusted): In adults under 65, a score <1.3 suggests low risk of advanced fibrosis, whilst >2.67 suggests higher risk. In adults aged 65 and over, a score <2.0 suggests low risk.

• NAFLD Fibrosis Score is an alternative validated tool.

• For indeterminate or high-risk scores, the Enhanced Liver Fibrosis (ELF) test (NICE DG34) may be used; a score ≥10.51 suggests advanced fibrosis and warrants referral to hepatology.

• Transient elastography (FibroScan) measures liver stiffness to assess fibrosis; the controlled attenuation parameter (CAP) quantifies the degree of steatosis.

NICE guidance emphasises the importance of identifying and managing underlying metabolic risk factors as the cornerstone of NAFLD treatment, as there are currently no licensed pharmacological therapies specifically for this condition. Patients with suspected advanced fibrosis should be referred to specialist hepatology services for further assessment and management.

Managing Liver Health While Taking Anastrozole

There is no established link between anastrozole use and the development or worsening of fatty liver disease in current medical literature and regulatory guidance. Anastrozole is primarily metabolised in the liver, but hepatotoxicity is uncommon, and the medication is not typically associated with significant hepatic steatosis. However, patients taking anastrozole may have pre-existing risk factors for fatty liver disease, including obesity, metabolic syndrome, or previous exposure to certain medications (such as tamoxifen), which can independently affect liver health.

According to the MHRA SmPC, no dose adjustment is required for patients with mild or moderate hepatic impairment. Anastrozole should be used with caution in patients with severe hepatic impairment due to limited data in this population.

For patients prescribed anastrozole, routine monitoring of liver function is not mandated by the MHRA or standard clinical protocols unless there are specific concerns or pre-existing liver conditions. However, it is pragmatic to consider baseline liver function tests (LFTs) in patients with known liver disease or metabolic risk factors, and to re-check LFTs if symptoms develop or if previous results were abnormal. Healthcare professionals may periodically check liver enzymes (ALT, AST) as part of comprehensive follow-up care, particularly if patients report unexplained fatigue or abdominal symptoms.

Practical strategies to support liver health during anastrozole therapy, in line with NICE NG49 guidance, include:

• Maintaining a healthy weight through balanced nutrition and regular physical activity—weight loss of 7–10% can significantly reduce liver fat

• Following a Mediterranean-style diet rich in vegetables, fruits, whole grains, lean proteins, and healthy fats

• Limiting alcohol consumption to within UK Chief Medical Officers' low-risk drinking guidelines (no more than 14 units per week, spread over at least three days)

• Managing comorbidities such as diabetes, hypertension, and dyslipidaemia through medication adherence and lifestyle modification

• Staying physically active with at least 150 minutes of moderate-intensity exercise weekly, as recommended by UK physical activity guidelines

Patients should inform their oncologist or GP about all medications and supplements they take, as some can interact with anastrozole or independently affect liver function. Do not take anastrozole with tamoxifen or oestrogen-containing therapies, as these reduce its effectiveness. Regular follow-up appointments provide opportunities to discuss any new symptoms and ensure holistic management of both cancer treatment and overall metabolic health.

When to Seek Medical Advice About Liver Concerns

Whilst serious liver problems are uncommon with anastrozole, patients should be aware of symptoms that warrant prompt medical evaluation. Contact your GP or specialist if you experience:

• Persistent or severe fatigue that interferes with daily activities and doesn't improve with rest

• Yellowing of the skin or whites of the eyes (jaundice)

• Dark urine or pale-coloured stools

• Unexplained abdominal pain or swelling, particularly in the upper right quadrant

• Persistent nausea, vomiting, or loss of appetite

• Easy bruising or unusual bleeding, which can suggest reduced liver synthetic function

• Itchy skin without an obvious dermatological cause

Seek urgent medical attention (contact 999 or attend A&E) if jaundice is accompanied by confusion, vomiting blood or passing black stools, severe abdominal swelling, marked drowsiness, or if you feel acutely unwell.

If you have been diagnosed with fatty liver disease or have risk factors such as diabetes or obesity, discuss this with your oncology team before starting anastrozole. They may recommend baseline liver function tests and establish an appropriate monitoring schedule tailored to your individual circumstances.

Patients already taking anastrozole who develop new liver-related symptoms should not stop their medication without medical guidance, as this could compromise cancer treatment. Instead, arrange a prompt consultation with your GP or oncologist to investigate the cause and determine the most appropriate course of action.

For those with established liver disease, anastrozole can often still be used safely. According to the MHRA SmPC, no dose adjustment is required for mild or moderate hepatic impairment, though caution is advised in severe hepatic impairment due to limited data. Clinical decisions should balance the benefits of continued cancer therapy against potential hepatic risks.

Regular health reviews provide the best opportunity to optimise both cancer treatment outcomes and overall metabolic health, ensuring that any liver concerns are identified and managed early in their course.

Remember: You can report any suspected side effects via the Yellow Card Scheme at yellowcard.mhra.gov.uk or through the Yellow Card app.

Frequently Asked Questions